Millennium Management LLC Cuts Position in uniQure (NASDAQ:QURE)

Millennium Management LLC trimmed its holdings in shares of uniQure (NASDAQ:QURE) by 78.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 464,535 shares of the biotechnology company’s stock after selling 1,725,446 shares during the period. Millennium Management LLC owned approximately 0.95% of uniQure worth $8,204,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Twin Tree Management LP purchased a new position in uniQure during the fourth quarter valued at $77,000. ADAR1 Capital Management LLC bought a new position in shares of uniQure during the fourth quarter valued at $177,000. China Universal Asset Management Co. Ltd. boosted its stake in uniQure by 9.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 969 shares in the last quarter. Wells Fargo & Company MN boosted its stake in uniQure by 13.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock worth $217,000 after purchasing an additional 1,503 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in uniQure during the 4th quarter valued at about $287,000. 78.83% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Matthew C. Kapusta sold 6,717 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $76,036.44. Following the transaction, the chief executive officer now owns 580,795 shares of the company’s stock, valued at $6,574,599.40. This trade represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christian Klemt sold 2,916 shares of uniQure stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the transaction, the chief financial officer now directly owns 155,168 shares in the company, valued at approximately $1,756,501.76. The trade was a 1.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock valued at $961,401 in the last 90 days. Company insiders own 4.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Cantor Fitzgerald upgraded shares of uniQure to a “strong-buy” rating in a research note on Monday, May 19th. Wells Fargo & Company cut their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday, February 28th. Guggenheim restated a “buy” rating and issued a $28.00 price target on shares of uniQure in a research note on Monday, May 12th. Chardan Capital reaffirmed a “buy” rating and set a $38.00 price target on shares of uniQure in a report on Monday, May 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of uniQure in a research report on Monday, April 21st. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and an average price target of $37.82.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $15.16 on Monday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $830.40 million, a PE ratio of -3.06 and a beta of 0.10. The firm’s 50 day moving average price is $12.44 and its 200-day moving average price is $12.68. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18.

uniQure (NASDAQ:QURE) last announced its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.25. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $1.57 million during the quarter, compared to analysts’ expectations of $5.93 million. Equities research analysts expect that uniQure will post -3.75 EPS for the current year.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.